Key statistics
Previous close$23.35
Open$23.16
Day high$23.71
Day low$22.59
52-week high$29.35
52-week low$15.73
Market cap11.68B
Volume4.51M
Average volume7.10M
P/E ratio10.87
Forward P/E—
EPS2.08
Dividend yield+0.88%
Market context
Why it moved
Baxter International shares declined as investor sentiment weakened amid broader market pressure from escalating U.S.-Iran geopolitical tensions, while ongoing concerns about the company's turnaround execution, margin pressure, and high debt levels continued to weigh on the stock near its consensus analyst price target.
What is happening
Recent company-specific developments and publisher coverage.
July 18, 2026Baxter International fell sharply, underperforming the broader healthcare sector, as a confluence of headwinds weighed on investor sentiment. A sector-wide selloff hit medical device stocks after Intuitive Surgical warned that shifting insurance coverage could dampen U.S. procedure volumes — a concern that dragged peers like Globus Medical and Enovis down 4–5%. For Baxter specifically, the pressure compounds existing challenges: a recently disclosed voluntary FDA Class I recall of its Hillrom VOLARA System respiratory circuit kits, a segment reporting restructuring into two new divisions (Medical Products & Therapies and Healthcare Systems & Technologies), and a Q1 2026 net loss of $15 million on $2.7 billion in sales. Goldman Sachs, which maintained a Neutral rating and raised its price target to $21 — still below current levels — reflects cautious Street sentiment toward a company navigating negative earnings, an effectively eliminated dividend, and an ongoing turnaround under new leadership.-3.1692
July 17, 2026Baxter International surged roughly 5% as investors reacted to a broad healthcare sector rally sparked by UnitedHealth Group's strong Q2 earnings beat, which lifted sentiment across the space. The move came amid a complex backdrop for Baxter: the company recently restructured into two reporting segments (Medical Products & Therapies and Healthcare Systems & Technologies), disclosed a $505M pre-tax loss for 2025, and is navigating a voluntary FDA Class I recall of its Hillrom VOLARA respiratory circuit kits. Goldman Sachs maintained a Neutral rating but raised its price target to $21, while Evercore ISI set a $24 target, reflecting divided analyst views on this speculative turnaround story.5.4176
July 16, 2026Baxter International closed up nearly 2% as the company unveiled a major reporting restructuring, consolidating from three segments into two — Medical Products & Therapies and Healthcare Systems & Technologies — and filing recast financials that highlight a $505 million pre-tax loss for 2025. The reorganization, effective Q2 2026, is being watched as a key step in Baxter's turnaround narrative under its new operating model, though Goldman Sachs maintained its Neutral rating while nudging its price target to $21 from $19 — still below the current price — amid lingering concerns including a nearly eliminated dividend, a Novum IQ pump shipment hold, and an ongoing FDA Class I recall of its Hillrom VOLARA respiratory device kits.1.6055
July 15, 2026Baxter International declined sharply, significantly underperforming the broader market on a day when the S&P 500 edged modestly higher on cooling inflation data. The selloff followed Goldman Sachs raising its price target to $21 from $19 while maintaining a Neutral rating—a target now essentially at the current price—alongside the company's announcement of a strategic realignment into two reporting segments (Medical Products & Therapies and Healthcare Systems & Technologies). A recent FDA enforcement action against Baxter's Hillrom Volara System added to investor unease, and the broader healthcare sector (XLV) also fell, weighed down by peers including Abbott, which dropped over 3%.-3.4116
July 11, 2026Baxter International edged higher on Thursday, though the stock slipped in after-hours trading amid a persistent bear case from Wall Street. Citi reiterated its Sell rating with a $17 price target on July 6, citing ongoing execution risks including IV fluid demand normalization and Novum IQ quality issues. Investor focus is now firmly on the company's Q2 2026 earnings call scheduled for July 30, with analysts expecting EPS of $0.37 — down 37% year-over-year — following a dual addition to the Russell 2500 and Russell 2500 Value indices last month that sparked a notable short-term rally.0.7124
July 10, 2026Baxter International shares rose, outperforming the broader healthcare sector (XLV was little changed) as investors responded to an Evercore ISI price target raise to $24 with a maintained Outperform rating, and Baxter's announcement of a July 30 earnings call for Q2 2026 results. The stock's recent dual addition to the Russell 2500 and Russell 2500 Value indices has also kept the name in focus, with analysts watching closely ahead of Q2 earnings where consensus calls for EPS of $0.37 — down year-over-year but with the company having beaten estimates in Q1.2.1838
July 9, 2026Baxter International fell nearly 4% — sharply underperforming the healthcare sector (XLV closed modestly lower) — as a broad risk-off session driven by President Trump's declaration that the U.S.-Iran ceasefire was 'over' weighed on equities. The selloff comes ahead of an anticipated Q2 2026 earnings report where analysts expect EPS of $0.37, down 37% year-over-year, and amid valuation debate following BAX's dual addition to the Russell 2500 and Russell 2500 Value indices on June 27, with some analysts flagging the stock as roughly 5% overvalued near its $21.54 fair value estimate. Evercore ISI maintained an Outperform rating with a raised $24 price target on July 6, though execution risks around IV fluid demand normalization and ongoing Novum IQ quality issues remain key investor concerns.-3.8495
July 8, 2026Baxter International shares rose, closing up over 1% and extending gains in after-hours trading, buoyed by a combination of company-specific catalysts and a strong healthcare sector tailwind. Evercore ISI raised its price target on Baxter to $24 while maintaining an "Outperform" rating, and the company was newly added to both the Russell 2500 Index and Russell 2500 Value Benchmark — moves that can drive index-tracking fund flows and expand investor awareness. Healthcare has been the S&P 500's best-performing sector for two consecutive weeks, with XLV near 52-week highs, providing a favorable backdrop even as analysts debate whether Baxter's recent 35%+ 90-day surge leaves it slightly overvalued near consensus fair value estimates.1.24
Seeking Alpha · July 19, 2026Baxter Stock: The Chart Points Higher, Valuation & Growth Are Less Appealing (NYSE:BAX)↗ad-hoc-news.de · July 19, 2026Baxter International stock trades steady as spin-off of kidney care business and margin focus shape↗Moomoo · July 15, 2026Goldman Sachs Adjusts Price Target on Baxter International to $21 From $19, Maintains Neutral Rating↗Simply Wall Street · July 15, 2026Is Baxter’s Class I Respiratory Device Recall Reshaping the Investment Case for Baxter International (BAX)?↗Investing.com · May 8, 2026Baxter International updates executive severance plan and amends bylaws after annual meeting↗Seeking Alpha · November 4, 2025Don't Write Off Baxter Just Yet (NYSE:BAX)↗ Benzinga · July 15, 2026Goldman Sachs Maintains Neutral on Baxter International, Raises Price Target to $21Mt Newswire · July 14, 2026Goldman Sachs Adjusts Price Target on Baxter International to $21 From $19, Maintains Neutral RatingBenzinga · July 6, 2026Evercore ISI Group Maintains Outperform on Baxter International, Raises Price Target to $24Mt Newswire · June 18, 2026Baxter International Unit Signs Distribution Deal for Surgical Visualization PlatformBenzinga · June 11, 2026FDA Issues Early Alert Regarding Pressure Breathing Device Issue from BaxterBenzinga · May 28, 2026Citigroup Downgrades Baxter International to Sell, Lowers Price Target to $17Mt Newswire · May 28, 2026Citigroup Downgrades Baxter International to Sell From Neutral, Adjusts PT to $17 From $19Benzinga · May 4, 2026Barclays Maintains Overweight on Baxter International, Raises Price Target to $27
